Harvard College

Bristol-Myers Squibb Compnay

Tufts University

Gokhan S Hotamisligil

Haiming Cao

Dariush Mozaffarian

Jeffrey A Robl

Michael Karin

Scott A Biller

Rex A Parker

Haris Jamil

Bruce L Jacobson

Krishna Kodukula

Lufen Chang

A method of reducing a symptom of a clinical disorder characterized by aberrantly elevated circulating aP2 is carried out by administering to a subject an inhibitor of secreted aP2, secretion of aP2, or a serum aP2 blocking agent. For example, glucose intolerance is reduced following administration of such an inhibitor or agent. Exemplary compositions inhibit cellular secretion of aP2 or bind to circulating aP2, thereby reducing the level or activity of aP2 in blood or serum.

Method of reducing glucose intolerance or insulin resistance in a patient in need thereof

Method of reducing blood glucose levels and inhibiting secreted aP2

Methods of treating diabetes by an adipocyte protein 2 specific antibody

The present invention provides for a novel lipokine, trans-C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, low concentrations of trans-C16:1n7-palmitoleate the serum indicates a risk of metabolic disease. Additionally, administering trans C16:1n7-palmitoleate to a subject (via pharmaceutical, nutraceutical, or other means), positively impacts glucose metabolism.

Use of trans-palmitoleate in identifying and treating metabolic disease

Method of treating lipodystrophy in HIV-infected humans

The present invention provides for a novel lipokine, C16:1n7-palmitoleate, which also serves as a biomarker for metabolic status. More specifically, a low concentration of C16:1n7-palmitoleate in the free fatty acid component of the serum indicates a risk of metabolic disease, and that de novo lipogenesis should be stimulated. Additionally, administering C16:1n7-palmitoleate to a subject (via nutraceutical or other means), positively impacts lipid metabolism.

Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status

A method is provided for treating atherosclerosis and related diseases, employing an aP2 inhibitor or a combination of an aP2 inhibitor and another antiatherosclerotic agent, for example, an HMG CoA reductase inhibitor such as pravastatin.

Method for treating atherosclerosis employing an aP2 inhibitor and combination

Disclosed herein are compositions and methods used to modulate a NH-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.

Compositions and methods for modulating NH2-terminal Jun Kinase activity

The invention provides compositions and methods of inhibiting Mal1 expression or function to treat lipid metabolisms disorders.

Growing community of inventors

Wellesley, MA, United States of America

Gokhan S Hotamisligil